CHM 11.1% 1.0¢ chimeric therapeutics limited

change in legal team, page-5

  1. 1,011 Posts.
    Surely given the implications and importance this places in the whole case of CHM's action, that something like this would need to have been reported to the ASX.

    Would seem an incredible lack of disclosure if it is the case.

    One thing is for sure though, when it comes to litigation, bigger is better!

    Bring it on.
 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.